INCY HALO Halozyme announces global collaboration and license agreement with Incyte to support the development of subcutaneous formulations

INCY HALO Halozyme announces global collaboration and license agreement with Incyte to support the development of subcutaneous formulations of inca033989 using its enhanze® technology Halozyme Therapeutics - to receive upfront payment and eligible for milestone payments from Incyte - Eligible to receive royalties on net sales of enhanze Medicines - Incyte granted rights to develop enhanze with mutcalr program and option for two additional targets